Molecular Pharmacology Program

The David Scheinberg Lab

Share
Back to top

Research

David Scheinberg
David A. Scheinberg, MD, PhD
Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Professor

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science. 

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021). 

Research Projects

The David Scheinberg Lab

Featured News

David Scheinberg, Chairman, Molecular Pharmacology and Chemistry Program
At Work: Center for Experimental Therapeutics Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.
Announcement
Pictured: Laurie Glimcher, Craig Thompson, Marc Tessier-Lavigne & Tadataka Yamada
Innovative Partnership Will Speed Drug Discovery and Development

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.
Scientists ID Antibody That Might Boost Cancer Therapy

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

View All Featured News

Publications

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

View All Publications

People

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Professor

  • Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
  • MD, PhD, Johns Hopkins University School of Medicine
[email protected]
Email Address
646-888-2190
Office Phone
View physician profile
Physician profile

Members

Michael Curcio

Research Assistant

Tao Dao

Senior Research Scientist

Tatyana Korontsvit

Research Assistant

Michael McDevitt
Michael R. McDevitt

Laboratory Member

Zita Aretz
Zita Aretz

Graduate Student

Christopher Bourne
Christopher Bourne

Graduate Student

Winson Cai

Graduate Student

Barbara de Mello
Barbara De Mello

Research Assistant

James Han

Research Associate

Keifer Kurtz
Keifer Kurtz

Graduate Student

Michael X. Lau
Michael X. Lau

Pediatric Hematology/Oncology Fellow

Josh Jaeyop Lee

Hematology/Oncology Fellow

Manish Malviya
Manish Malviya

Senior Research Scientist

Jeremy P. Meyerberg

Research Technician

Stephanie Pierre, BS
Stephanie Pierre

Graduate Student

Ekaterina Revskaya
Ekaterina Revskaya

Senior Research Scientist

Pedro Silberman

Graduate Student

Kristen Vogt
Kristen Vogt

Graduate Student

Patrick Wallisch, MSc
Patrick Wallisch

Graduate Student

Lab Alumni
Emily C. Casey, BS
Emily C. Casey

Principal Scientific Communication Lead at Genentech, San Francisco, CA

Aaron Chang

Graduate Student

Freddie Escorcia
Thomas J. Gardner, PhD
Thomas J. Gardner

Research Fellow

Ron Gejman
Ron Gejman

Graduate Student

William Maguire

Graduate Student

Prabodhika Mallikaratchy, PhD
Prabodhika Mallikaratchy

Visiting Scientist

Justin J. Mulvey

Graduate Student

Andrew Scott

Research Technician

Jonathan Seideman

Graduate Student

Nicholas Veomett

Graduate Student

Carlos Villa

Graduate Student

Sam Wong

Graduate Student

Victoriya Zakhaleva, Research Technician
Victoriya Zakhaleva

Research Technician

Bryan Aristega

Research Technician

Mamadou A. Bah

Lab Rotation SEP-DEC 2020

Megan Dacek
Megan Dacek

Graduate Student

Casey Jarvis

Research Technician

Heather Jones

Graduate Student

Martin G. Klatt

Research Fellow

Melissa Mathias

Research Fellow

Sung Soo Mun

Research Assistant

Leila Peraro

Research Scholar

Lab Affiliations

Lab News & Events

Journal Club & Photo Album

Get in Touch

Lab Resources

To learn more about Postdoc compensation and benefits at MSK, please visit https://www.mskcc.org/education-training/postdoctoral/resources-postdocs/compensation-benefits-resources

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Arvinas, Inc.
    Ownership / Equity Interests
  • Bridge Medicines
    Provision of Services (uncompensated)
  • CoImmune, Inc.
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Ensysce Bioscience
    Ownership / Equity Interests
  • Eureka Therapeutics Inc
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Great Point Partners
    Ownership / Equity Interests; Provision of Services
  • Iovance Biotherapeutics, Inc.
    Ownership / Equity Interests
  • Lantheus Medical Imaging, Inc.
    Ownership / Equity Interests
  • OncoPep, Inc.
    Provision of Services
  • Pfizer, Inc.
    Ownership / Equity Interests; Provision of Services
  • Repertoire Immune Medicines, Inc.
    Provision of Services
  • Sapience Therapeutics, Inc.
    Fiduciary Role/Position; Ownership / Equity Interests
  • Sellas Life Science Group
    Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures

Related topics: